EU Panel Recommends Dupilumab (Dupixent) for Eczema

Troy Brown, RN


July 21, 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for dupilumab (Dupixent, Sanofi/Regeneron Pharmaceuticals) for the treatment of adults with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Dupilumab will be available as a 300-mg injectable solution. It is a recombinant human IgG4 monoclonal antibody that inhibits the signaling of interleukin-4 and interleukin-13.

In three clinical trials, dupilumab improved skin condition in patients with atopic dermatitis as measured by improved scores on the Investigator Global Assessment and Eczema Area and Severity Index-75 scales. It also relieved itching.

In March this year, the US Food and Drug Administration approved dupilumab for moderate to severe atopic dermatitis not adequately controlled with topical therapies or for use when those therapies are contraindicated.

The most frequent adverse effects seen with dupilumab are injection site reactions, conjunctivitis, blepharitis, and oral herpes.

Dupilumab should be prescribed by physicians experienced in treatment of atopic dermatitis.

The European public assessment report will publish the summary of product characteristics, which will include detailed recommendations for dupilumab use. The summary will be published in all official European Union languages after the European Commission grants marketing authorization.

For more news, join us on Facebook and Twitter


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.